sakacin A: from Lactobacillus sake; effective against strains of L. monocytogenes [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 382302 |
| CHEMBL ID | 1970519 |
| CHEBI ID | 185674 |
| MeSH ID | M0194079 |
| Synonym |
|---|
| 3-amino-4-[1-[[tert-butyl(methyl)carbamoyl]amino]ethylamino]-4-oxo-butanoic acid |
| 3-amino-4-((1-(((tert-butyl(methyl)amino)carbonyl)amino)ethyl)amino)-4-oxobutanoic acid |
| NCI60_024404 |
| nsc-669764 |
| nsc669764 |
| CHEBI:185674 |
| sakacin a |
| 3-amino-4-[1-[[tert-butyl(methyl)carbamoyl]amino]ethylamino]-4-oxobutanoic acid |
| 145266-47-3 |
| CHEMBL1970519 |
| 3-amino-3-[(1-{[tert-butyl(methyl)carbamoyl]amino}ethyl)carbamoyl]propanoic acid |
Sakacin A is a small, heat-stable, antilisterial bacteriocin. It is produced by Lactobacillus sake Lb706.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Sakacin A is a small, heat-stable, antilisterial bacteriocin produced by Lactobacillus sake Lb706. " | ( The genes involved in production of and immunity to sakacin A, a bacteriocin from Lactobacillus sake Lb706. Axelsson, L; Holck, A, 1995) | 1.98 |
| "Sakacin A is an antilisterial bacteriocin produced by Lactobacillus sake Lb706. " | ( Cloning and nucleotide sequence of a gene from Lactobacillus sake Lb706 necessary for sakacin A production and immunity. Aukrust, T; Axelsson, L; Birkeland, SE; Blom, H; Holck, A, 1993) | 1.95 |
| "Sakacin A is a bacteriocin produced by Lactobacillus sakei Lb706. " | ( The synthesis of the bacteriocin sakacin A is a temperature-sensitive process regulated by a pheromone peptide through a three-component regulatory system. Axelsson, L; Diep, DB; Grefsli, C; Nes, IF, 2000) | 2.03 |
| Class | Description |
|---|---|
| aspartic acid derivative | An amino acid derivative resulting from reaction of aspartic acid at the amino group or either of the carboxy groups, or from the replacement of any hydrogen of aspartic acid by a heteroatom. The definition normally excludes peptides containing aspartic acid residues. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (41.38) | 18.2507 |
| 2000's | 10 (34.48) | 29.6817 |
| 2010's | 6 (20.69) | 24.3611 |
| 2020's | 1 (3.45) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (16.11) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (3.33%) | 5.53% |
| Reviews | 1 (3.33%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 28 (93.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||